the mean relative change in pioglitazone pharmacokinetic
parameters following gemfibrozil administration
was significantly influenced by CYP2C8 genotype
(Table 3, Figure 3). Specifically, CYP2C8*3 carriers had a
mean 5.2-fold increase in pioglitazone AUC(0,•) compared
with a mean 3.3-fold increase in CYP2C8 *1 homozygotes
(P = 0.02) following gemfibrozil administration.The relative
change in pioglitazone t1/2 was also larger in CYP2C8 *3
carriers compared with CYP2C8 *1 homozygotes (3.3-fold
vs. 2.9-fold), although this difference did not reach statistical